|
|
| Blue
Bell, PA – February 29, 2008 – |
|
VGX Pharmaceuticals Inc. (VGX) announced today that
Professor David B. Weiner of the University of Pennsylvania will serve
as the Chairman of the DNA Vaccines Asia 2008 Conference next week in
Seoul, Korea. Professor Weiner is a pioneer in the field of DNA vaccines
and a VGX co-founder.
The conference—the first of such meetings in Asia—will bring
together the pioneering scientists and thought leaders of DNA vaccines
and therapies in Asia and the US. The conference will be held on March
4th and has an agenda covering a broad range of topics including current
DNA vaccine research, product development and manufacturing. In addition
to Professor Weiner, the conference speakers include Professor Shan Lu
of University of Massachusetts, Professor Bin Wang of China Agriculture
University, Professor Chang-yuil Kang of Seoul National University, Professor
Eiji Kobayashi of Jichi Medical School, and Dr. Ruxandra Draghia-Akli
of VGX Pharmaceuticals and other distinguished experts in the field of
DNA vaccines and therapies. The delegates at the conference represent
professionals from biotechnology companies, major pharmaceutical companies,
academic institutions, and government labs throughout Asia. The conference
is sponsored by VGX and Biologics Resources, Inc.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with small molecule
and biologic product candidates for the treatment of infectious diseases,
cancer, and inflammatory diseases. The Company's clinical development
programs include PICTOVIR™ for HIV infection, which is in Phase
II clinical trials, and PENNVAX™-B, a DNA vaccine for HIV infection,
which is in 2 separate Phase I clinical trials. The Company’s lead
compound for inflammatory diseases, VGX-1027, is also in Phase I clinical
trials. VGX has established a vertically-integrated DNA Vaccines and Therapies
Platform with extensive capabilities including SynCon™ DNA-based
product candidates, the patented CELLECTRA™ delivery device, and
efficient cGMP plasmid manufacturing facilities. The cGMP facilities are
used for VGX’s own product supplies and for contract manufacturing.
Vertical control over key aspects of product development has enabled the
Company to consistently develop multiple product candidates, from bench-to-IND
filing, within 1 year. The product candidates and technology programs
are protected by the Company's extensive global intellectual property
portfolio. More information about VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
